Wells Fargo Reports Improved Earnings In Q3

Wells Fargo & Company (WFC) on Thursday reported earnings that increased from last year particularly helped by a decrease in provision for loan losses. However, net interest income and non-interest income dropped from last year.

Net income was $5.122 billion or $1.17 per share in the third quarter, higher than $3.216 billion or $0.70 per share in the same quarter a year ago.

Revenue for the quarter declined to $18.834 billion from $19.316 billion last year on lower net interest income.

Net interest income decreased 5% to $8.909 billion in the third quarter from $9.379 billion a year ago, due to soft demand and higher prepayments.

Non interest income was $9.925 billion compared with $9.937 billion last year.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.99 per share on revenue of $18.35 billion for the quarter. Analysts' estimate typically exclude special items.

The company said provision for credit losses in the third quarter decreased about $1.7 billion from the previous year and reported an allowance of $1.395 billion, due to continued improvements in the economic environment, as well as a significant decrease in net charge-offs.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT